about
Bisphosphonates in multiple myeloma: a network meta-analysisBisphosphonates in multiple myelomaEarly versus deferred treatment for early stage multiple myelomaHealth related quality of life in patients with multiple myeloma undergoing a double transplantation.Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma. A phase II International Oncology Study Group study.A pilot study of bortezomib in Korean patients with relapsed or refractory myelomaThalidomide-associated thrombocytopenia.Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma.Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myelomaPrevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patientsOver-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistancePeripheral neuropathy in cancer patients.Thalidomide in the treatment of multiple myeloma.Thalidomide for the treatment of relapsed and refractory multiple myeloma.Immunotherapy in multiple myeloma: current strategies and future prospects.Protocol of a multi-centre randomised controlled trial of a web-based information intervention with nurse-delivered telephone support for haematological cancer patients and their support personsPrognostic Significance of Initial Serum Albumin and 24 Hour Daily Protein Excretion before Treatment in Multiple Myeloma.Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains.A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myelomaThalidomide for the treatment of multiple myeloma.A prognostic index for multiple myeloma.Current treatment options for myeloma.Multiple myelomas in cats.Combination of cyclophosphamide, etoposide, carboplatin and dexamethasone as a salvage regimen for refractory multiple myeloma patients: a comparison with a historical control group.Superparamagnetic nanoparticle clusters for cancer theranostics combining magnetic resonance imaging and hyperthermia treatment.Possible intrinsic association of anti-neutrophil cytoplasmic antibody-associated vasculitis coexisting with multiple myeloma.Complete C4 vertebral body destruction: a dramatic finding in a patient with a new diagnosis of myeloma.Evolving therapeutic paradigms for multiple myeloma: back to the future.Therapeutic effects of thalidomide in hematologic disorders: a review.Novel 19 F-MRS β-galactosidase reporter molecules incorporated nitrogen mustard analogues.Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines.Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma.Hyaluronan, a major non-protein glycosaminoglycan component of the extracellular matrix in human bone marrow, mediates dexamethasone resistance in multiple myeloma.Elevated level of plasma basic fibroblast growth factor in multiple myeloma correlates with increased disease activity.Modulation of interleukin-6/interleukin-6 receptor cytokine loop in the treatment of multiple myeloma.Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and amyloidosis?Human herpesvirus 8 (KSHV) contamination of peripheral blood and autograft products from multiple myeloma patients.Whither the bone marrow transplant?Transplant-related mortality in patients older than 60 years undergoing autologous hematopoietic stem cell transplantation.
P2860
Q24197839-C13F15DC-EF0D-41A9-A48B-9096ECC3C42EQ24236776-EFB43B00-96CD-4CFE-B3BD-76F3C81F91B4Q24250249-2114E29B-0581-4EE8-8D82-052DC2CDC076Q33210966-E7FE14F7-F6A6-4FAC-ABB8-2C98B96CCF9DQ33343690-FA7EE4FE-49BD-4936-9A9F-B64DC6D96041Q33367833-FB388598-4C8B-43DD-ABB3-985EF35D2894Q33368888-0476456D-90CA-4955-9F27-48C495FD8755Q33404570-C714321E-B729-42EC-BB14-2CF6F33A61FDQ33503261-67DB33DB-F353-4C76-816E-7880D2773DF8Q33648344-190987F1-AE93-463A-AF02-7ED936EAAFC2Q34031441-B2701E4D-A2B9-4B60-8D99-CB9DC9879EF9Q34175179-CCABD9D7-D034-4CFB-A8DF-B12CA442B12DQ34280846-9C593F28-21D0-49C9-96FC-9918D97E7AA7Q34734291-A9892774-DAE6-4ADD-A497-3293B6E7AE9AQ34782279-EA3A9F92-C61C-4983-AE5B-9DC44D7D550EQ35194182-F11F7DB5-87A9-4987-9301-B4993FB02A7CQ35552563-9CC38892-3BFC-43AE-B3CB-A63DFE04C66DQ35656808-F1CEEA17-75F0-4FA1-A7C1-7B94FA21F7F0Q35824530-37546099-7662-48C1-A956-47935CBA8E46Q35848744-05184A6C-EEC5-43E5-9B4B-7787E5E1C408Q35870500-68C3A6C2-39A1-44C4-8C22-54D8E310D362Q36134864-900384E3-0F7C-4298-9606-0C36548A7A57Q36163971-FF9E8E6B-4C69-4C7F-B824-DE1BC46BDD67Q36236351-970B6D3B-4D2E-4B7C-A318-255BDD134BC1Q36331737-6DFFDDEA-5055-488D-8FD9-43491635DBCDQ36915312-4A49B3B5-DE92-429B-AC22-C9D3DAA1DA9CQ37205840-F64D8B91-0571-4746-9C4C-DB611D9E0D99Q37597982-110B13B1-DA30-424F-BF76-7C89F3984B8FQ38033590-D35EC002-A31E-4A11-A377-2ADC38B28838Q38121762-AA4322FB-0E80-4AC9-9828-83DBC4295D6BQ38831996-9B06C89F-7314-45B7-A896-5DE1B86E9D36Q40273844-58D90A14-9A60-4B22-88A6-3C5EDE53C07FQ40629636-7F391420-72F2-47EB-8F7B-50EA14C48361Q40655653-5B9F107F-80D9-4E4A-9DD1-FDB1B399D2EDQ40734914-948B0F76-ECC4-45E6-928A-611EDDE39D1AQ40875040-EB4A9281-9C94-4061-A705-BEBB06935D6CQ41030369-53CF70A1-4679-46BF-AFAE-1EA94BBC7839Q41719288-C9DB0FD2-76E7-4091-8823-94C0C0A0F58CQ43173269-FA5A3B7C-97F1-47AB-961B-2A333BDB8E53Q43539736-694A19A8-A7C2-4DB8-AD31-02E042A96CBA
P2860
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
The treatment of multiple myeloma.
@en
type
label
The treatment of multiple myeloma.
@en
prefLabel
The treatment of multiple myeloma.
@en
P1476
The treatment of multiple myeloma.
@en
P2093
Alexanian R
P304
P356
10.1056/NEJM199402173300709
P407
P577
1994-02-01T00:00:00Z